Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Radioimmunotherapy with alpha-particle-emitting immunoconjugates.

R M Macklis1, B M Kinsey, A I Kassis

  • 1Joint Center for Radiation Therapy, Harvard Medical School, Boston, MA 02115.

Science (New York, N.Y.)
|May 20, 1988
PubMed
Summary

This study developed an alpha-particle radioimmunoconjugate targeting the Thy 1.2 antigen. The targeted therapy demonstrated selective cancer cell killing and cured ascites in mice, suggesting potential for intracavitary cancer treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Surveying the Challenges to Improve Linear Accelerator-based Radiation Therapy in Africa: a Unique Collaborative Platform of All 28 African Countries Offering Such Treatment.

Clinical oncology (Royal College of Radiologists (Great Britain))·2021
Same author

Developing Innovative, Robust and Affordable Medical Linear Accelerators for Challenging Environments.

Clinical oncology (Royal College of Radiologists (Great Britain))·2019
Same author

Mobilising Expertise and Resources to Close the Radiotherapy Gap in Cancer Care.

Clinical oncology (Royal College of Radiologists (Great Britain))·2016
Same author

Cytokine Dysregulation in Acute Graft-versus-Host Disease.

Hematology (Amsterdam, Netherlands)·2016
Same author

Public health oncology: a framework for progress in low- and middle-income countries.

Annals of oncology : official journal of the European Society for Medical Oncology·2012
Same author

Normal tissue protection for improving radiotherapy: Where are the Gaps?

Translational cancer research·2012

Area of Science:

  • Oncology
  • Radiochemistry
  • Immunology

Background:

  • Alpha particles offer high cytotoxicity due to their high linear energy transfer.
  • Radioimmunoconjugates combine targeted delivery with potent therapeutic payloads.
  • The Thy 1.2 antigen is present on specific murine T cell and neuroectodermal tumors.

Purpose of the Study:

  • To prepare and evaluate an alpha-particle-emitting radioimmunoconjugate for cancer therapy.
  • To assess the selective cytotoxicity of the conjugate against Thy 1.2-positive tumor cells.
  • To determine the in vivo efficacy of the radioimmunoconjugate in a murine ascites model.

Main Methods:

  • Preparation of a bismuth-212-labeled monoclonal immunoglobulin M targeting Thy 1.2.
  • In vitro cytotoxicity assays using EL-4 murine tumor cells.

Related Experiment Videos

  • In vivo studies involving intraperitoneal inoculation of EL-4 cells and conjugate administration.

    • Main Results:

    • The radioimmunoconjugate exhibited selective cytotoxicity against Thy 1.2+ EL-4 cells in vitro.
    • A low ratio of conjugate to target cells (approximately 3:1) was sufficient to abolish [3H]thymidine uptake.
    • Intraperitoneal administration of the radioimmunoconjugate cured ascites in mice inoculated with EL-4 cells.

    Conclusions:

    • Bismuth-212-labeled radioimmunoconjugates targeting Thy 1.2 are selectively cytotoxic to relevant tumor cells.
    • This targeted alpha-particle therapy shows promise for intracavitary cancer treatment.
    • Further investigation into radioimmunoconjugate therapy for cancers expressing Thy 1.2 is warranted.